COVID-19 outbreak and cancer radiotherapy disruption in Italy: Survey endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO): Radiotherapy and Oncology

B.A. Jereczek-Fossa, M. Pepa, G. Marvaso, A. Bruni, M. Buglione di Monale e Bastia, G. Catalano, A.R. Filippi, P. Franco, M.A. Gambacorta, D. Genovesi, G. Iatì, A. Magli, L. Marafioti, I. Meattini, A. Merlotti, M. Mignogna, D. Musio, R. Pacelli, S. Pergolizzi, V. TomboliniM. Trovò, U. Ricardi, S.M. Magrini, R. Corvò, V. Donato

Research output: Contribution to journalArticlepeer-review

Abstract

Italy experienced one of the world's deadliest COVID-19 outbreaks and healthcare systems had to instantly reorganise activity. The Italian Radiation Oncology Departments adapted numerous solutions to minimize the disruptions. Information technologies, treatment prioritization and implementation of hypofractionation and protection procedures allowed balancing between cancer patient care and patient/healthcare workers safety. © 2020 Elsevier B.V.
Original languageEnglish
Pages (from-to)89-93
Number of pages5
JournalRadiother. Oncol.
Volume149
DOIs
Publication statusPublished - 2020

Keywords

  • AIRO (Italian Association of Radiotherapy and Clinical Oncology)
  • COVID-19
  • Italy
  • Radiation oncology
  • Survey
  • Article
  • cancer patient
  • cancer radiotherapy
  • clinical practice
  • coronavirus disease 2019
  • human
  • outpatient
  • patient care
  • priority journal
  • questionnaire
  • radiation oncology
  • sanitation
  • Betacoronavirus
  • Coronavirus infection
  • epidemic
  • legislation and jurisprudence
  • neoplasm
  • oncology
  • pandemic
  • virus pneumonia
  • Coronavirus Infections
  • Disease Outbreaks
  • Humans
  • Medical Oncology
  • Neoplasms
  • Pandemics
  • Pneumonia, Viral
  • Surveys and Questionnaires

Fingerprint

Dive into the research topics of 'COVID-19 outbreak and cancer radiotherapy disruption in Italy: Survey endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO): Radiotherapy and Oncology'. Together they form a unique fingerprint.

Cite this